M. D. Anderson Cancer Center - News Releases 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Study identifies eight signs associated with impending death in cancer patients
Researchers at The University of Texas MD Anderson Cancer Center
have identified eight highly specific physical and cognitive signs
associated with imminent death in cancer patients. The findings,
published in the journal Cancer, could offer clinicians the ability to
better communicate with patients and families. They may also guide both
the medical team and caregivers on complex decision making, such as
discontinuation of tests and therapy, plans for hospital discharge and
hospice referral. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - February 9, 2015 Category: Cancer & Oncology Source Type: news
'Jekyll and Hyde' protein both prevents and spreads cancer
Scottish author Robert Louis Stevenson tapped into primal fears when he penned "Dr. Jekyll and Mr. Hyde," a 19th century novel about a sinister physician, raising the question, "Can evil and good exist in the same person?" (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - February 9, 2015 Category: Cancer & Oncology Source Type: news
Cancer's ability to 'hijack' regulatory mechanism increases metastasis
When skyscrapers go up, contractors rely on an infrastructure of steel
beams and braces. Some cancers grow the same way, using a biological
matrix from which the tumor can thrive and spread. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - February 9, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson, AstraZeneca enter collaboration to help improve patient outcomes in ovarian and gynecologic cancers
The University of Texas MD Anderson Cancer Center
and AstraZeneca today announced a multiyear strategic research
collaboration to conduct multiple, parallel clinical and clinically
related studies in ovarian and other gynecologic cancers with the aim of
improving patient outcomes. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 29, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson and Bayer announce collaboration to create symptom assessment questionnaires in clinical trials
When cancer patients take part in a clinical trial to develop new
therapies, they and their physicians want to know how they will feel and
function during treatment. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 23, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson receives top Chinese science and technology award
The University of Texas MD Anderson Cancer Center was presented the People's Republic of China International Science and Technology Cooperation Award at a ceremony held Jan. 9 at Beijing's Great Hall of the People (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 16, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson presents 10th Making Cancer History® Seminar in West Palm Beach
Renowned oncologists from The University of Texas MD Anderson Cancer Center
return to West Palm Beach Jan. 31 for the institution's well-known
Making Cancer History® educational seminar. Doctors will discuss their
innovative research in breast and prostate cancers, share vital cancer
prevention tips and update attendees on breakthroughs made possible by
the Moon Shots Program, MD Anderson's unprecedented effort to rapidly reduce cancer deaths. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 15, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson study finds patients with metastatic colorectal cancer having less surgery, yet survival rates improving
With the dawn of the modern era of new chemotherapeutic and biologic agents available for managing their disease, patients with metastatic colorectal cancer are undergoing less surgery for the removal of their primary tumors, according to research from The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 14, 2015 Category: Cancer & Oncology Source Type: news
Intrexon, ZIOPHARM and MD Anderson in Exclusive CAR T Pact
Intrexon Corporation, a leader in synthetic biology and its oncology partner, ZIOPHARM Oncology, today announced a broad exclusive licensing agreement with The University of Texas MD Anderson Cancer Center, including an exclusive sublicensing agreement through MD Anderson for intellectual property developed at the University of Minnesota for the development of non-viral adoptive cellular cancer immunotherapies. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 13, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson and Amgen announce agreement to develop BiTE® therapies for myelodysplastic syndrome
The University of Texas MD Anderson Cancer Center and Amgen have announced a research collaborative agreement focusing on Amgen's bispecific T cell engager (BiTE®) antibody constructs, an immunotherapy that serves as a "bridge" between T cells and cancer cells. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 12, 2015 Category: Cancer & Oncology Source Type: news
Novel Anti-Cancer Drug, ONC201, Focus of Alliance Between Oncoceutics and MD Anderson
Oncoceutics Inc. and The University of Texas MD Anderson Cancer Center today announced the initiation of a strategic alliance and research collaboration agreement for the clinical development of ONC201, a novel anti-cancer drug. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - January 5, 2015 Category: Cancer & Oncology Source Type: news
MD Anderson, UnitedHealthcare Launch New Cancer Care Payment Model
The University of Texas MD Anderson Cancer Center and UnitedHealthcare have launched a pilot to explore a new cancer care payment model for head and neck cancers that focuses on quality patient care and outcomes. The collaboration is among the first using bundled payments in a large, comprehensive cancer center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 16, 2014 Category: Cancer & Oncology Source Type: news
Texas legislators Invest In Ovarian Cancer Research at MD Anderson
The KK125 Ovarian Cancer Research Foundation,
established by State Rep. Ken King (R-Canadian), District 88, and State
Rep. Kyle Kacal (R-College Station), District 12, has donated $50,000
to ovarian cancer research at The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 16, 2014 Category: Cancer & Oncology Source Type: news
MD Anderson applauds FDA approval of HPV vaccine
The Food and Drug Administration's (FDA) approval of a new vaccine that targets five additional strains of human papilloma virus (HPV) fortifies a proven cancer-prevention weapon, according to Ronald A. DePinho, M.D., president of The University of Texas MD Anderson Cancer Center. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 11, 2014 Category: Cancer & Oncology Source Type: news
Diagnostic Tool Reduces Chemotherapy Rates Post-Surgery In Women With Breast Cancer
In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center
have found that the commercial diagnostic tool, Oncotype DX, was
associated with a decrease in chemotherapy use in younger patients, but
not in those over 66 years of age. (Source: M. D. Anderson Cancer Center - News Releases)
Source: M. D. Anderson Cancer Center - News Releases - December 11, 2014 Category: Cancer & Oncology Source Type: news
